Valuation Abbott Laboratories Bulgaria S.E.
Stocks
ABL
US0028241000
Medical Equipment, Supplies & Distribution
|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 91.53 EUR | +23.56% |
|
0.00% | -30.19% |
| 08-03 | Is everything under control? |  |
| 07-31 | Amgen discloses data breach involving patient health information | RE |
Company Valuation: Abbott Laboratories
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 241,365 | 191,427 | 191,088 | 196,184 | 217,859 | 182,486 | - | - |
| Change | - | -20.69% | -0.18% | 2.67% | 11.05% | -16.24% | - | - |
| Enterprise Value (EV) 1 | 249,166 | 198,318 | 198,871 | 202,693 | 222,266 | 206,652 | 203,902 | 200,102 |
| Change | - | -20.41% | 0.28% | 1.92% | 9.66% | -7.02% | -1.33% | -1.86% |
| P/E | 35.7x | 28.1x | 33.8x | 14.8x | 33.7x | 30.2x | 23.3x | 20.9x |
| PBR | 6.93x | 5.2x | 4.94x | 4.11x | 4.18x | 3.79x | 3.63x | 3.42x |
| PEG | - | -36.9x | -2x | 0x | -0.7x | -4.94x | 0.8x | 1.8x |
| Capitalization / Revenue | 5.6x | 4.39x | 4.76x | 4.68x | 4.91x | 3.63x | 3.34x | 3.12x |
| EV / Revenue | 5.78x | 4.54x | 4.96x | 4.83x | 5.01x | 4.11x | 3.73x | 3.43x |
| EV / EBITDA | 19.4x | 15.9x | 19.5x | 19.1x | 18.9x | 15.9x | 14.1x | 12.7x |
| EV / EBIT | 22x | 17.7x | 22.3x | 21.8x | 21.6x | 17.6x | 15.7x | 14x |
| EV / FCF | 28.8x | 25.4x | 39.3x | 31.9x | 30.1x | 26.1x | 21.8x | 19.6x |
| FCF Yield | 3.47% | 3.94% | 2.54% | 3.13% | 3.33% | 3.84% | 4.59% | 5.1% |
| Dividend per Share 2 | 1.82 | 1.92 | 2.08 | 2.24 | 2.4 | 2.57 | 2.711 | 2.799 |
| Rate of return | 1.29% | 1.75% | 1.89% | 1.98% | 1.92% | 2.44% | 2.57% | 2.65% |
| EPS 2 | 3.94 | 3.91 | 3.26 | 7.64 | 3.72 | 3.492 | 4.522 | 5.038 |
| Distribution rate | 46.2% | 49.1% | 63.8% | 29.3% | 64.5% | 73.6% | 60% | 55.6% |
| Net sales 1 | 43,075 | 43,653 | 40,109 | 41,950 | 44,328 | 50,304 | 54,649 | 58,413 |
| EBITDA 1 | 12,815 | 12,485 | 10,188 | 10,635 | 11,735 | 12,959 | 14,453 | 15,807 |
| EBIT 1 | 11,324 | 11,231 | 8,911 | 9,295 | 10,301 | 11,718 | 13,019 | 14,321 |
| Net income 1 | 7,071 | 6,933 | 5,723 | 13,402 | 6,524 | 6,255 | 7,923 | 8,786 |
| Net Debt 1 | 7,801 | 6,891 | 7,783 | 6,509 | 4,407 | 24,166 | 21,416 | 17,615 |
| Reference price 2 | 140.74 | 109.79 | 110.07 | 113.11 | 125.29 | 105.46 | 105.46 | 105.46 |
| Nbr of stocks (in thousands) | 1,714,968 | 1,743,574 | 1,736,059 | 1,734,455 | 1,738,834 | 1,730,383 | - | - |
| Announcement Date | 26/01/22 | 25/01/23 | 24/01/24 | 22/01/25 | 22/01/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 19.64x | 3.43x | 12.05x | 3.43% | 110B | |
| 17.04x | 0.19x | 12.04x | 0.77% | 59.59B | |
| 31.84x | 7.93x | 20.18x | 1.25% | 55.04B | |
| 37.06x | 3.28x | 11.2x | 2.31% | 46.87B | |
| 40.3x | 1.45x | 12.76x | 0.2% | 35.55B | |
| 35.2x | 6.18x | 19.4x | -.--% | 32.81B | |
| 40.57x | 7.11x | 25.5x | 0.26% | 24.54B | |
| 25.62x | 3.75x | 13.16x | 1.12% | 22.69B | |
| 20.25x | 2.79x | 10.8x | 1.56% | 21.75B | |
| Average | 29.72x | 4.01x | 15.23x | 1.21% | 45.47B | |
| Weighted average by Cap. | 27.56x | 3.80x | 14.50x | 1.65% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- ABT Stock
- ABL Stock
- Valuation Abbott Laboratories
Select your edition
All financial news and data tailored to specific country editions
